Bain & gain

Bain Capital Life Sciences’ inaugural fund is looking to distinguish itself from other multi-strategy healthcare funds by focusing exclusively on growth capital opportunities. The fund will be largely agnostic to disease area, geography and technology, and will mainly zero in on assets nearing value inflection points.

The fund closed at $720 million on May 23, with $600 million from external investors and $120 million from Bain Capital LP partners...